Alector ^{Priced, Nasdaq: ALEC}

We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. We are developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. Supporting our scientific approach, our Discovery Platform enables us to advance a broad portfolio of product candidates, validated by human genetics, which we believe will improve the probability of technical success over shorter development timelines. As a result, in the last five years, we have identified over forty immune system targets, progressed over ten programs into preclinical research, and advanced two product candidates, AL001 and AL002, into clinical development. In the second half of 2018, AL001, initially aimed at treating FTD-GRN patients, was dosed in forty-two healthy subjects in a single ascending dose Phase 1 study. There were no serious adverse events or dose limiting adverse events reported in the study, achieving the primary endpoint.